|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||||||||
  BJU InternationalVolume 100 Issue 1, Pages 107 - 110 Published Online: 5 Jun 2007 © 2010 BJU International
Abstract | References | Full Text: HTML, PDF (Size: 91K) | Related Articles | Citation Tracking  The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder Copyright © 2007 THE AUTHORS; JOURNAL COMPILATION © 2007 BJU INTERNATIONAL KEYWORDS bladder diaries • efficacy • overactive bladder • tolterodine extended-release OBJECTIVE
To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI). PATIENTS AND METHODSWe conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (≥8 voids/24 h) and UUI (≥5 episodes/week) for ≥ 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight. RESULTSCompared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval. CONCLUSIONSThese results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night. Accepted for publication 25 January 2007 | 
|
.gif)